Get the Stockscreener App
0.5899
9.20%
0.0497
Entero Therapeutics Inc stock is traded at $0.5899, with a volume of 40,423.
It is up +9.20% in the last 24 hours and down -4.86% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$0.5402
Open:
$0.54
24h Volume:
40,423
Relative Volume:
0.22
Market Cap:
$2.58M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+17.98%
1M Performance:
-4.86%
6M Performance:
-9.23%
1Y Performance:
+0.00%
1-Day Range:
$0.52
$0.5899
1-Week Range:
$0.4802
$0.625
52-Week Range:
$0.185
$3.00
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
0.5899 | 2.58M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.75 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.16 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
667.51 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.46 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.28 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Entero Therapeutics Inc Stock (ENTO) Latest News
AzurRx BioPharma Announces Results of Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency - Marketscreener.com
Entero Therapeutics faces Nasdaq delisting over meeting lapse By Investing.com - Investing.com Australia
Entero Therapeutics faces Nasdaq delisting over meeting lapse - Investing.com
Entero therapeutics CFO sells $465 in stock - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SUM, STAF, ALVR, ENTO on Behalf of Shareholders - The Malaysian Reserve
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of SUM, ENTO, ALVR and STAF - GlobeNewswire Inc.
ENTO (Entero Therapeutics) Price-to-Operating-Cash-Flow : (As of Dec. 04, 2024) - GuruFocus.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
First Wave BioPharma, Inc. announced that it expects to receive $4 million in funding - Marketscreener.com
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - News & Insights
Entero Therapeutics faces financial obligations acceleration By Investing.com - Investing.com Nigeria
Entero Therapeutics faces financial obligations acceleration - Investing.com India
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders - Marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
Finansavisen - Finansavisen
Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - AccessWire
ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc.ENTO - Marketscreener.com
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum - The Manila Times
Entero Therapeutics announces proposed reverse merger with Journey Therapeutics - TipRanks
Entero finds lifeline in reverse merger with nano-immunoconjugate firm Journey - FirstWord Pharma
Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Entero, Journey to merge, creating oncology-focused biopharma By Investing.com - Investing.com Canada
Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. in a reverse merger transaction. - Marketscreener.com
Entero stock in focus amid reverse merger plans (ENTO:NASDAQ) - Seeking Alpha
Entero, Journey to merge, creating oncology-focused biopharma - Investing.com
Entero Therapeutics Announces Proposed Reverse Merger with - GlobeNewswire
Entero Therapeutics Announces 99% Reverse Merger Deal with Journey's Cancer Platform | ENTO Stock News - StockTitan
FIRST WAVE BIOPHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
AzurRx BioPharma, Inc. Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients - Marketscreener.com
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients - Marketscreener.com
Layoff Tracker: Marinus Cuts Employees After Disappointing Phase III Trial - BioSpace
How Are Things Looking For Entero Therapeutics Inc. (NASDAQ: ENTO) For The Short Term? - Stocks Register
Entero therapeutics CFO sells shares to cover tax obligations By Investing.com - Investing.com South Africa
Entero therapeutics CFO sells shares to cover tax obligations - Investing.com India
Entero Therapeutics Inc.’s Market Journey: Closing Weak at 0.42, Down -19.41 - The Dwinnex
Taking on analysts’ expectations and winning: Entero Therapeutics Inc. (ENTO) - SETE News
Potential Price Increase for Entero Therapeutics Inc. (ENTO) After Recent Insider Activity - Knox Daily
Market cap of Entero Therapeutics Inc. [ENTO] reaches 1.95M – now what? - The DBT News
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.51%
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):